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Background: Therapeutic options for patients with non-small cell lung cancer (NSCLC) are often restricted to
systemic chemotherapy. However, the molecular and cellular processes during chemotherapy of advanced
NSCLC patients still remain unclear. Here we investigated the stimulatory activity of plasma in advanced NSCLC
patients and its correlation with chemotherapy.
Methods: Whole blood samples from advanced NSCLC patients were collected before the first, second, and
third cycle of chemotherapy. Plasma was isolated following centrifugation of whole blood. PBMCs were isolated
from whole-blood specimens by Ficoll-Hypaque density gradient centrifugation. Immune complexes (ICs) were
isolated from NSCLC plasma using the IgG Purification Kit. qRT-PCR was used to detect a broad array of cytokines
and chemokines.
Results: The plasma in advanced NSCLC patients was endowed with stimulatory activity and capable of inducing
proinflammatory cytokines. Both nucleic acids and immunoglobulin components were required for the stimulatory
activity of NSCLC plasma. In consistent, TLR8 and TLR9 conferred the stimulatory activity of plasma in NSCLC patients.
Of note, we revealed the decreased stimulatory activity of plasma in patients who responded to chemotherapy.
Conclusions: Our findings demonstrated that the plasma of advanced NSCLC patients required TLR-stimulating nucleic
acid immunoglobulin complexes and could discriminate the responsiveness to chemotherapy, which might provide a
novel mechanism by which the proinflammatory immune response was induced and a potential new biomarker for
evaluating responsiveness to chemotherapy in NSCLC patients.
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Lung cancer is the leading cause of cancer-related death
worldwide [1]. Approximately 85% of lung cancers are
non-small cell lung cancer (NSCLC), most of which areFigure 1 The plasma of NSCLC patients was endowed with stimulator
in the presence of 20% plasma derived from normal donors or from NSCLC
serum). Data points represented individual patients. *P < 0.001 (B) PBMCs d
tested for the expression of the indicated cytokines using quantitative PCR
volunteers or from 28 NSCLC patients.only diagnosed at advanced stages when therapeutic
options are often restricted to systemic chemotherapy
[1–4]. However, chemotherapeutic treatments for NSCLC
are still relatively ineffective [5]. A better understanding ofy activity. (A) PBMCs derived from normal volunteers were cultured
patients before treatment, or control plasma (20% fetal bovine
erived from 16 normal volunteers or from 28 NSCLC patients were
. *P < 0.001. Each bar represented the means (±SD) from 16 normal
Figure 2 (See legend on next page.)
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Figure 2 Nucleic acid and protein in plasma were required for their stimulatory activity. (A-C) PBMCs derived from normal volunteers
were cultured with 20% plasma derived from NSCLC patients before treatment in the presence of the indicated dose of DNase, RNase and
Papain respectively. (D and E) PBMCs derived from normal volunteers were cultured with 20% plasma derived from NSCLC patients before
treatment (D) or the isolated immune complexes (IC) (E) in the presence of the of DNase (20units), RNase (5units) and Papain (20 μl) respectively. *P < 0.01.
Data points represented individual patients.
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therapy of advanced NSCLC patients was urgently
needed.
Recent study revealed the presence of endogenous
nucleic acid-immunoglobulin complexes in the plasma
of cancer patients [6]. It has been known for some time
that endougenous nucleic acid-immunoglobulin com-
plexes could induce the proinflammatory responses
efficiently [6–8]. Accumulating data showed that the
plasma proinflammatory cytokines were associated with
the progression of NSCLC in patients [5,9–12]. These
studies implicated a potential stimulatory effect of
plasma in NSCLC patients. However, the stimulatory
effect of plasma in advanced NSCLC patients and its
correlation with their response to chemotherapy still
remain unclear.
Here we reported that nucleic acid-immunoglobulin
complexes in plasma from NSCLC patients could effect-
ively induce proinflammatory cytokines through Toll like
receptor (TLR) 8 and TLR9. We revealed a reduced
stimulatory activity of plasma in patients who responded
to chemotherapy. Our findings provided a novel mechan-
ism by which the proinflammatory immune response was
initiated and propagated and a promising new method for
discriminating the response to chemotherapy in advanced
NSCLC patients.Results
The NSCLC plasma could induce proinflammatory
response
To detect whether the plasma of NSCLC patients was
endowed with stimulatory activity, we detected the proin-
flammatory cytokines generated from PBMCs of healthy
controls following exposure to plasma collected from the
NSCLC patients prior to chemotherapy. We found that the
NSCLC plasma was effectively to induce the production of
cytokines including IL-1β, IL-8 IL-6, IL-12, IFN-α and
TNF-α (Figure 1A, P < 0.05). In contrast, exposure of nor-
mal PBMCs to normal plasma or to control plasma re-
sulted in no significant generation of proinflammatory
cytokines (Figure 1A, P > 0.05). Consistently, we analyzed
the expression of cytokines in PBMCs isolated from
NSCLC patients prior to the treatment, and found that
the expression of cytokines in PBMCs was higher in
NSCLC patients than that in healthy controls (Figure 1B,
P < 0.05).Nucleic acid and protein were required for the
stimulatory activity of NSCLC plasma
When plasma from NSCLC patients were pretreated
with DNase or RNase and then incubated with the nor-
mal PBMCs, as shown in Figure 2A and B, we found
that pretreatment of plasma with DNase and RNase
could significantly abrogated the induction of IL-8, IFN-
α and TNF-α in a dose dependent manner (P < 0.05),
suggesting that nucleic acid was crucial for stimulatory
activity of NSCLC plasma. Further, pretreatment of
plasma with immobilized papain could also inhibit the
induction of IL-8, IFN-α and TNF-α in a dose
dependent manner (Figure 2C, P < 0.05), suggesting that
the immunoglobulin (Ig) component was also important
for the stimulatory activity of NSCLC plasma. Besides,
when normal PBMCs were incubated with NSCLC
plasma pretreated with DNase plus papain or RNase
plus papain, the induction of IL-8, IFN-α and TNF-α de-
creased further (Figure 2D, P < 0.05). These data indi-
cated that nucleic acid-immunoglobulin complexes in
plasma might be responsible for the stimulatory effect of
NSCLC plasma. Indeed, when normal PBMCs were in-
cubated with ICs isolated from the NSCLC plasma prior
to chemotherapy, as shown in Figure 2E, we observed an
significant expression of cytokines, which could be abro-
gated by pretreatment with DNase, RNase and papain
(P < 0.05).
TLR8 and TLR9 conferred the stimulatory activity of
NSCLC plasma
We then explored the potential role of TLRs in induc-
tion of cytokines by NSCLC plasma using human em-
bryonic kidney (HEK) cells transfected with TLR3, TLR4,
TLR8, and TLR9 respectively. We found that 4 of 5
NSCLC plasmas effectively induced the expression of
IL-8 in HEK cells transfected with TLR8 and TLR9,
which could be enhanced by co-transfection with CD32
(Figure 3A and B, P < 0.05). These data suggested that
TLR8 and TLR9 were required for the stimulatory effect
of NSCLC plasma. To confirm these results, normal
PBMCs were transfected with shRNA targeting TLR3,
TLR4, TLR8 and TLR9, and then stimulated with the
NSCLC plasma collected before chemotherapy. As
shown in Figure 3C, we found that transfection with
shRNA effectively down-regulated their mRNA expres-
sion respectively (P < 0.05). Of important, transfection
with shRNA targeting TLR8 and TLR9, but not TLR3
Figure 3 (See legend on next page.)
Xu et al. Cancer Cell International 2014, 14:80 Page 5 of 10
http://www.cancerci.com/content/14/1/80
(See figure on previous page.)
Figure 3 TLR8 and TLR9 conferred the stimulatory activity of plasma of NSCLC patients. (A) HEK cells transfected with TLR3, TLR4, TLR8
and TLR9 were incubated with 20% plasma from NSCLC patients before treatment for 6 h, and then assayed for the expression of IL-8 using
quantitative PCR. Negative controls were HEK transfectants stimulated with plasma from normal adult volunteers. Positive controls were HEK
transfectants stimulated with TLR agonists. (B) TLR8 and TLR9-expressing HEK cells were co-transfected with CD32-expression vector and then
stimulated with 20% plasma from NSCLC patients before treatment for 6 h. *P < 0.001. (C and D) PBMCs derived from normal volunteers were
transfected with the indicated TLR shRNA respectively for 24 h, and then cultured with 20% plasma derived from NSCLC patients before treatment for 6 h.
The efficacy of TLR shRNA was evaluated by detecting their relative mRNA expression. *P < 0.01. (E) HEK cells transfected with the indicated TLR with or
without CD32 were incubated with the isolated IC from NSCLC plasma before treatment for 6 h. *P < 0.001. Data points represented individual patients.
Each bar represented the means (±SD) from 5 NSCLC patients.
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(Figure 3D, P < 0.05). Finally, we confirmed that ICs iso-
lated from the NSCLC plasma could effectively induce
the expression of cytokines through TLR8 and TLR9 but
not TLR3 and TLR4 (Figure 3E and data not shown).
The stimulatory activity of NSCLC plasma was decreased
in patients who responded to chemotherapy
When we analyzed the stimulatory activity of NSCLC
plasma in the responders and nonresponders of ad-
vanced NSCLC patients to chemotherapy, as shown in
Figure 4A, we found that exposure to NSCLC plasma
from responsive patients before the second and third
cycle of chemotherapy resulted in a decreased induction
of cytokines in normal PBMCs. In contrast, plasma iso-
lated from the nonresponders before the first, second
and third cycle of chemotherapy induced a generally
comparable level of cytokines (Figure 4B, P > 0.05).
These findings indicated that the plasma from re-
sponders exerted a reduced stimulatory activity. In con-
sistent, we found a decreased expression of cytokines in
PBMCs of responders after the first and the second cycle
of chemotherapy (Figure 4C, P < 0.05). The expression of
cytokines in PBMCs of nonresponders was generally
comparable during the first and second cycle of chemo-
therapy (Figure 4D, P > 0.05).
Discussion
The discovery of a series of innate immune-specific re-
ceptors activated by pathogen associated molecular pat-
terns led to a new understanding of innate immunity
mechanisms [13,14]. Among the innate immune-specific
receptors, the best characterized are the Toll like recep-
tors (TLRs), which are primary identified mainly on cells
of the immune system, and play an essential role in
adaptive immunity [15–17]. Recently, accumulating data
suggested that TLRs were involved in the development
of antitumor immunity [18–21]. In lung cancer patients,
accumulating evidence suggested that TLR9 signaling
played a crucial role in anti-tumor immunity [22–24].
However, TLR9 response to CpG oligonucleotide (ODN)
in human lung cancer cells could also enhance their
growth and invasive potential in vitro and in vivo [25–
31]. Besides, TLR9 signaling could increase the releaseof VEGF in a mouse model of lung cancer [32]. There-
fore, the potential role of TLRs in tumor immunity was
complex and still deserved to be elucidated. Our current
study showed that NSCLC plasma could induce the pro-
inflammatory cytokines. Of note, TLR8 and TLR9 signal-
ing contributed to the generation of proinflammatory
immune responses in advanced NSCLC patients. In
addition, NSCLC plasma effectively induced expressions
of pro-inflammatory cytokines from autologous NSCLC
PBMCs (Additional file 1: Figure S1). Our findings were
consistent with previous studies, which showed that the
nucleic acid-immunoglobulin complexes were effect to
induce immune response and thus played crucial roles
in autoimmune disease and antitumor immunity [6,7],
and provided a novel insight into the production of pro-
inflammatory cytokines in NSCLC patients.
In present study, we revealed a reduced stimulatory activ-
ity of plasma in NSCLC patients who responded to chemo-
therapy. Our data were in line with previous evidence
which showed that high levels and insufficient decreases of
nucleosomes during the first cycle of chemotherapy indi-
cated poor outcome of NSCLC patients [33], and the previ-
ous study which found that the circulating tumor cells and
tumor DNA in peripheral blood was associated with clinical
response to chemotherapy in NSCLC patients [1]. Our re-
sults suggested that reduced chemotherapy resistance was
associated with TLR-stimulating nucleic acid immuno-
globulin complexes in peripheral blood of advanced
NSCLC patients. However, the precise mechanisms by
which the nucleic acid-immunoglobulin complexes were
generated and involved in antitumor immunity undoubt-
edly need successive studies.
We should acknowledge some limitations of this study.
The clinical sample size in this study was relatively small,
and thus, large-scale studies were needed. The precise
mechanisms by which the nucleic acid-immunoglobulin
complexes were generated and involved in antitumor im-
munity undoubtedly needed successive studies. In addition,
the findings should be tested at individual level to further
the translational study.
Conclusions
Our results suggested that the stimulatory activity of
plasma in the form of TLR-stimulating nucleic acid
Figure 4 (See legend on next page.)
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Figure 4 Reduced stimulatory activity of plasma in patients who responded to chemotherapy. (A and B) PBMCs derived from normal volunteers
were cultured with 20% plasma derived from NSCLC patients who responded to chemotherapy (A) or not responded to chemotherapy (B) before
treatment, after the first cycle and after the second cycle of chemotherapy respectively. Data points represented individual patients. *P < 0.01. (C and D)
PBMCs derived from NSCLC patients who responded to chemotherapy (C) or not responded to chemotherapy (D) before treatment, after the first cycle
and after the second cycle of chemotherapy respectively, and then assayed for their expression of the indicated cytokines. Each bar represented the
means (±SD) from 12 responders or 16 nonresponders.
Table 1 Characteristics of the advanced NSCLC patients
Characteristics n=28
















Abbreviations: CMV caboplatin + mitomycin c + Vinblastin, MV mitomycin c +
Vinorelbin, GC gemcitabine + cisplatin.
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NSCLC was associated with their chemotherapy resist-
ance. These findings might provide a novel mechanism
by which proinflammatory immune responses were initi-
ated and propagated in NSCLC patients and a potential




This study was approved by the Ethics Committee of
Tongji University. The collection and storage of patient
medical information was analyzed anonymously. The
peripheral blood samples were collected after obtaining
written informed consent.
Patients
A total of 28 patients with newly diagnosed NSCLC
(stages III and IV) without infection were recruited, and
all the peripheral blood samples were collected after
obtaining informed consent. The clinical characteristics
of NSCLC patients were summarized in Table 1. Normal
controls (n = 16) were recruited and all were in excellent
health at the time of the study.
Classification of response to chemotherapy
The classification of response to chemotherapy was per-
formed as previously described [33]. Before start of the
third cycle of chemotherapy, staging investigations were
done consisting of clinical examination, whole body com-
puted tomography, and laboratory examinations. The re-
sponse to therapy was classified according to the World
Health Organization classifications defining “remission” as
reduction of the tumor volume ≥50%, “progression” as in-
crease of the tumor volume ≥25% or appearance of new
tumor manifestations, and “no change” as reduction of the
tumor volume <50% or increase <25%. In this study, 12 pa-
tients reached remission (42.9%), 11 suffered from progres-
sion (39.3%), and 5 had no change of disease (17.8%). The
patients with “progression” and “no change” were joined to
the group of nonresponders to therapy, whereas patients
with remission were classified as responders to therapy.
Sample Collection and preparation
Whole-blood samples were collected before the first, sec-
ond, and third cycle of chemotherapy for determination oftheir stimulatory effect of plasma. Plasma was isolated fol-
lowing centrifugation of whole blood. PBMCs were isolated
from whole-blood specimens by Ficoll-Hypaque density
gradient centrifugation (Sigma-Aldrich).Detection of cytokines
qRT-PCR was used to detect a broad array of cytokines
and chemokines, using gene specific sense and anti-sense
primers, as previously described [6,7]. In experiments using
PBMCs, PBMCs (2 × 106/ml) were stimulated with condi-
tioned medium containing 20% of NSCLC plasma (vol/vol).
Specifically, 1 million cells in suspension were stimulated
with either TLR agonist or 20% patient plasma for 6 hours
prior to harvesting cells for RNA extraction. In experiments
using TLR-expressing cell lines, cells were seeded at 2 × 105
cells/well, rested in RPMI 1640 overnight, and then ex-
posed to either TLR agonists or 20% patient plasma for the
indicated time. Exposure to 20% of a single lot of fetal bo-
vine plasma was used as a negative control. Relative quanti-
fication of gene expression was normalized against the
housekeeping gene GAPDH.
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and protease
Isolation of ICs and treatment of plasma with nucleases
and protease were achieved as previously described [6].
Immune complexes (ICs) were isolated from patient
plasma using the IgG Purification Kit (Pierce) per the
manufacturer’s instructions. To test the role of nucleic
acids in the immunostimulatory activity of test plasma,
20 μl patient plasma were treated with 20 units of
DNase I (Ambion) or 5 units of RNase (Promega) for
30 minutes at room temperature before stimulation of
cells. Protease treatment of test plasma was achieved
using 20 μl of immobilized papain (Pierce) for 4 h at
room temperature prior to stimulation of cells.
TLR transfected HEK293 cells and TLR siRNA
HEK293 cells stably expressing human TLR3, TLR4, TLR8,
TLR9, and control cells, the TLR agonist as well as the
shRNA targeting human TLR3, TLR4, TLR8 and TLR9,
were all purchased from Invivogen and used according to
the instructions.
Statistical analyses
Data are presented as the mean ± standard deviation
from three independent experiments performed in tripli-
cate. T tests were used for statistical analyses using the
program PRISM 6.0 (GraphPad Software Inc., San Diego,
CA, USA). P < 0.05 was considered to be significant.
Additional file
Additional file 1: Figure S1. NSCLC plasma induced expressions of
pro-inflammatory cytokines from autologous NSCLC PBMCs. (A) NSCLC
plasma was incubated with HC PBMCs or autologous NSCLC PBMCs.
respectively and detected for IL-8 and TNF-α expressions. Each bar represented
themeans (±SD) from 3 normal controls and 3 NSCLC patients.
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